MedTrace Logo

Sulforadex in Healthy Volunteers SAD

NCT01948362 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2013-09-23

No results posted yet for this study

Summary

To determine the safety and tolerability of single escalating doses of Sulforadex® in healthy male volunteers.

Conditions

  • Stage, Prostate Cancer

Interventions

DRUG

Sulforadex

Active compound

DRUG

Alpha cyclodextrin

Placebo control

Sponsors & Collaborators

  • Evgen Pharma

    lead INDUSTRY

Principal Investigators

  • Jörg Täube, MD FFPM · Richmond Pharmacology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01948362 on ClinicalTrials.gov